IMO's ophthalmologists, optometrists and nurses who specialise in ocular photography conduct several multi-centre clinical trials each year. These studies are in addition to the basic research projects pioneered by the Molecular Biology Laboratory.
IMO's ophthalmologists, optometrists and nurses who specialise in ocular photography conduct several multi-centre clinical trials each year. These studies are in addition to the basic research projects pioneered by the Molecular Biology Laboratory.
Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.
Post-Market Clinical Follow-up study of the TECNIS Symfony plus Extended Range of vision Intraocular Lens Model ZHR00
Multi-center, randomized, double masking, controlled, multicenter Phase III study with active comparator to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema.
Extension study, open and multicentre to assess the safety and tolerability of long-term lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a study sponsored by ROCHE.
Phase IV clinical trial to evaluate genetic variants of the VEGF pathway as biomarkers of efficacy of aflibercept treatment in patients with neovascular age-related macular degeneration (AMD).
Evaluation of the effectiveness of aflibercept intravitreous injection (IVT) in clinical practice in non treated patients with Neovascular Age-Related Macular Degeneration.
Clinical trial to evaluate the effects of Fydrane® and standard topical mydriatics and anaesthetics protocol on ocular surface after cataract surgery.
Performance and safety assessment of t4020 combined with standard post-operative therapy versus standard post-operative therapy in managing corneal epithelial defect following epi-off accelerated corneal cross-linking.
A double-masked study of SYL1001 in patients with moderate to dry eye disease (DED)
An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME)
A randomized, double-blind, phase IV clinical study with simulated control for the analysis of the efficacy, safety and tolerability of aflibercept intrevitrea monotherapy compared to aflibercept and concomitant photodynamic therapy in patients with polypodal choroidal vasculopathy.
Phase IV clinical trial to evaluate the efficacy of aflibercept in Naïve patients with macular edema secondary to central retinal vein occlusion (CRVO) in Treat and extend (TAE) individualized treatment regimen.
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00.
Phase III, multicentre, randomised, double-blind, sham-controlled trial to assess the efficacy and safety of lampalizumab administered by intravitreal injection to patients with geographic atrophy secondary to age-related macular degeneration.
Open-label phase IV trial to examine the change of vision-related quality of life in subjects with diabetic macular oedema (DMO) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment.
Phase IV: Prevention of macular oedema in cataract surgery. PREMED. Non-commercial research.
Phase III: Two-year, randomised, double-blind, multicentre, two-group trial comparing the efficacy and safety of 6 mg RTH258 compared to aflibercept in subjects with wet age-related macular degeneration.
Efficacy and safety of slow-release bimatoprost in patients with open-angle glaucoma or ocular hypertension.
Randomised, active-controlled, parallel group, phase III trial on the efficacy, safety and tolerability of 2 mg aflibercept administered with intyravidial injections using two different regimens of treatment for subjects with neovascular age-related macular degeneration.
Safety and efficacy of abiciparpegol (AGN-150998) in patients with neovascular age-related macular degeneration.
Phase II, multicentre, randomised, double-masked, 4 parallel arms, controlled, 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post-treatment safety follow-up in moderate to severe dry eye patients.
Phase IV, randomised, double-blind trial with simulated control for the analysis of the efficacy, safety and tolerability of aflibercept intravenous monotherapy compared to aflibercept and concomitant photodynamic therapy in patients with polypodal choroidal vasculopathy.
Compensation for blindness with the Intelligent Retinal Implant System (IRIS V2) in patients with retinal dystrophy.
Phase III: Assessment of the efficacy and safety of a fixed combination of unpreserved latanoprost drops and timolol 0.5% (T2347) versus Xalacom® in patients with ocular hypertension or glaucoma.
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00.